Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade?) versus Biosimilar Infliximab (Renflexis?) for Acute Severe Ulcerative Colitis.

Cappuccio JM, Mehta N, Pellish R. Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade?) versus Biosimilar Infliximab (Renflexis?) for Acute Severe Ulcerative Colitis. Dig Dis. 2024; 42(5):496-502.

View in: PubMed

subject areas

Acute Disease
Adult
Biosimilar Pharmaceuticals
Colitis, Ulcerative
Cost Savings
Drug Costs
Female
Gastrointestinal Agents
Hospitalization
Humans
Infliximab
Inpatients
Male
Middle Aged
Retrospective Studies

authors with profiles

Randall S Pellish MD